In particular, fetal tumor organoids were sensitive to the treatment of small molecule inhibitors targeting the EGFR/HER, such as afatinib, erlotinib, and sapitinib, while embryonal tumor organoids were sensitive to pan-FGFR inhibitors, such as erdafitinib, futibatinib, and ponatinib (Fig. 6f, g, Supplementary Fig. 6b and Supplementary Table 2). Here, EGFR is linked to neoplasm.